Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. [electronic resource]
Producer: 20200601Description: 1607-1618 p. digitalISSN:- 1349-7006
- Animals
- Apoptosis -- drug effects
- Carcinoma, Renal Cell -- drug therapy
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Kidney Neoplasms -- drug therapy
- Mice
- Mice, Nude
- Protein Kinase Inhibitors -- pharmacology
- Signal Transduction -- drug effects
- Sirolimus -- analogs & derivatives
- Sunitinib -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.